
2024 Symposium Abstracts: The Promise of PRRT in Neuroendocrine Tumor Treatment - Recorded November 22nd, 2024
Falha ao colocar no Carrinho.
Falha ao adicionar à Lista de Desejos.
Falha ao remover da Lista de Desejos
Falha ao adicionar à Biblioteca
Falha ao seguir podcast
Falha ao parar de seguir podcast
-
Narrado por:
-
De:
Sobre este áudio
In this episode of NETCAST, neuroendocrine experts Dr. Mosalem and Dr. Wahl meet with Taymeyah Al-Toubah discuss the latest advancements in neuroendocrine tumor treatments, focusing on peptide receptor radionuclide therapy (PRRT) with alpha and beta emitters. They delve into the safety and efficacy of new investigational agents, the challenges of hematological toxicity, and the importance of multidisciplinary teams in managing patient care. The conversation highlights the evolving landscape of neuroendocrine tumor therapies and the need for ongoing research and collaboration.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.